Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
BIOTECHNOLOGY VALUE FUND L P - 14 May 2026 SCHEDULE 13D/A Report for XOMA Royalty Corp Common Stock, $0.0075 par value (XOMA)
- Filing manager
- BIOTECHNOLOGY VALUE FUND L P
- Reporting owner
- BVF PARTNERS L P/IL
- Beneficially owned shares
- 7,593,303 shares
- Large-stake signal
-
Ownership
43%Beneficial ownership of this reported class.
Shares
7,593,303 sharesShares beneficially owned as disclosed.
Event date
14 May 2026Date tied to the ownership event or amendment.
Accepted by SEC
18 May 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 43%
- Symbol
- XOMA
- Shares outstanding
- 17,536,497 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 18 May 2026, 17:26:17 UTC
- Event date
- 14 May 2026
- Prior SEC filing
- 29 Apr 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
BIOTECHNOLOGY VALUE FUND L P disclosed 43% ownership in XOMA Royalty Corp Common Stock, $0.0075 par value (XOMA) on 14 May 2026.
Key facts
- BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13D/A for XOMA Royalty Corp Common Stock, $0.0075 par value (XOMA).
- Disclosed ownership: 43%.
- Date of event: 14 May 2026.
Change
- Previous schedule filing date: 29 Apr 2026.
- Current filing was accepted on 18 May 2026, 17:26.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (10)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 21% | 3,635,758 | 0 | 3,635,758 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0000918923 |
| BVF I GP LLC | 21% | 3,635,758 | 0 | 3,635,758 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001803805 |
| BIOTECHNOLOGY VALUE FUND II LP | 16% | 2,773,545 | 0 | 2,773,545 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001102444 |
| BVF II GP LLC | 16% | 2,773,545 | 0 | 2,773,545 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001803806 |
| Biotechnology Value Trading Fund OS LP | 2.3% | 412,000 | 0 | 412,000 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001660683 |
| BVF Partners OS Ltd. | 2.3% | 412,000 | 0 | 412,000 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001660684 |
| BVF GP HOLDINGS LLC | 36% | 6,409,303 | 0 | 6,409,303 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001803809 |
| BVF PARTNERS L P/IL | 43% | 7,593,303 | 0 | 7,593,303 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001055947 |
| BVF INC/IL | 43% | 7,593,303 | 0 | 7,593,303 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | 0001056807 |
| LAMPERT MARK N | 43% | 7,593,303 | 0 | 7,593,303 | /s/ Mark N. Lampert | Mark N. Lampert | 0001233840 |
CIK / CUSIP context first